A Japanese company has received the green light to mass-manufacture a treatment for Parkinson’s that transplants stem cells directly into the brain. In a seven-person study no adverse effects were observed and more than half the participants showed some signs of recovery. Because the study was so small, the license is provisional: patients will continue to be monitored and if the drug proves dangerous, it will be withdrawn. https://parkinsonsnewstoday.com/news/japan-grants-conditional-approval-amchepry-parkinsons/
#ShareGoodNewsToo